CLSD

$0.00

(

0.00%

)
Quote details

stock

Clearside Biomedical Inc

NASDAQ | CLSD

3.34

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$17.48M

Market Cap

-

P/E Ratio

-5.11

EPS

$17.10

52 Week High

$3.32

52 Week Low

HEALTHCARE

Sector

CLSD Chart

Recent Chart
Price Action

CLSD Technicals

Tags:

CLSD Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.5M
Total Revenue $1.7M
Cost Of Revenue $149K
Costof Goods And Services Sold $149K
Operating Income -$29M
Selling General And Administrative $12M
Research And Development $19M
Operating Expenses $30M
Investment Income Net -
Net Interest Income -$8.3M
Interest Income $1.5M
Interest Expense $9.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $226K
Income Before Tax -$34M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$34M
Comprehensive Income Net Of Tax -
Ebit -$25M
Ebitda -$24M
Net Income -$34M

Revenue & Profitability

Earnings Performance

CLSD Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $25M
Total Current Assets $21M
Cash And Cash Equivalents At Carrying Value $20M
Cash And Short Term Investments $20M
Inventory -
Current Net Receivables $507K
Total Non Current Assets $3.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $747K
Other Non Current Assets -
Total Liabilities $64M
Total Current Liabilities $4.8M
Current Accounts Payable $1.5M
Deferred Revenue -
Current Debt -
Short Term Debt $375K
Total Non Current Liabilities $59M
Capital Lease Obligations $703K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $52M
Other Current Liabilities $3M
Other Non Current Liabilities $52M
Total Shareholder Equity -$39M
Treasury Stock -
Retained Earnings -$355M
Common Stock $77K
Common Stock Shares Outstanding $4.9M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$25M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $226K
Capital Expenditures $977K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$638K
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$34M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.5M
Total Revenue $1.7M
Cost Of Revenue $149K
Costof Goods And Services Sold $149K
Operating Income -$29M
Selling General And Administrative $12M
Research And Development $19M
Operating Expenses $30M
Investment Income Net -
Net Interest Income -$8.3M
Interest Income $1.5M
Interest Expense $9.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $226K
Income Before Tax -$34M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$34M
Comprehensive Income Net Of Tax -
Ebit -$25M
Ebitda -$24M
Net Income -$34M

CLSD Profile

Clearside Biomedical Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Clearside Biomedical, Inc. is a biopharmaceutical company headquartered in Alpharetta, Georgia, focused on the development of groundbreaking therapies for serious ocular diseases related to vision loss. Utilizing its proprietary SCS Microinjector technology, Clearside enhances drug delivery directly to the suprachoroidal space, thereby improving treatment efficacy for conditions such as uveitis and macular edema. With a robust pipeline of innovative solutions and strategic partnerships, the company is positioned to significantly impact the ophthalmology sector and address substantial unmet medical needs, reinforcing its role as a key player in vision preservation.

WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
PLUG
-7.12%
$2.08
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
RGTI
-3.10%
$24.69
AAL
-3.29%
$12.34
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
MU
-1.97%
$241.95
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
SMR
-6.19%
$21.06
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
NBIS
+2.92%
$85.98
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
JOBY
-3.60%
$13.89
WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
PLUG
-7.12%
$2.08
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
RGTI
-3.10%
$24.69
AAL
-3.29%
$12.34
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
MU
-1.97%
$241.95
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
SMR
-6.19%
$21.06
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
NBIS
+2.92%
$85.98
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
JOBY
-3.60%
$13.89

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.